Synthesis a new radiopharmaceutical for prostate cancer SPECT imaging

Prostate cancer (PCa) is the second tumor most diagnosed in men and their sixth cause of death worldwide. A prompt detection of cancer development could avoid invasive therapy and improve general survival. The prostate-specific membrane antigen (PSMA) is one of the most promising targets for the detection of PCa, since that it’s overexpressed in more than 95% of tumor tissue. In the last years, PSMA-based monoclonal antibody (mAb) radiopharmaceuticals showed a great specificity to early localize PCa and its metastasis. Recently, an Iodine-131 labelled single-chain variable fragment, obtained from the mAb D2B (131I-scFvD2B), demonstrated a high uptake in PSMA-tumor cells and a fast clearance from the non-target tissue2,3. In this work, a new radiopharmaceutical for SPECT imaging based on scFvD2B labelled with technetium-99m (99mTc-HYNIC-GGC-scFvD2B) was synthetized